Prevents Pneumocystis jirovecii pneumonia (PCP). ANDA 209685, held by Glenmark Specialty. Atovaquone.
As of Nov 21, 2026, ANDA 209685 (Atovaquone), held by Glenmark Specialty, was first approved by FDA on Nov 21, 2018, with 3 approved supplements and 0 published complete response letters.
Atovaquone oral suspension is a quinone antimicrobial drug indicated for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 21, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML · suspension;oral | Atovaquone | Rx |
| Jun 8, 2026 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 1, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Nov 1, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 21, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters